Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Eli Lilly beats Q1 estimates, raises 2026 outlook on strong GLP-1 drug sales

LLY

$1,157.46

+$0.83 +0.07%

Eli Lilly beats Q1 estimates, raises 2026 outlook on strong GLP-1 drug sales

Company Fundamentals

30 Apr 2026

Proactive Investors

View Source

Bullish

Eli Lilly reported Q1 2026 earnings with adjusted EPS of $8.55, surpassing estimates, and revenue of $19.8 billion, up 56% year-over-year. The growth was driven by high demand for diabetes and obesity drugs Mounjaro and Zepbound. Lilly raised its full-year revenue guidance to $82-$85 billion and adjusted EPS to $35.50-$37, citing FDA approval of Foundayo, a new oral GLP-1 therapy expected to expand patient access. The company also announced positive clinical trial results and acquisitions to boost its pipeline in RNA, oncology, and biologics.

More News (LLY)

Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.

Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...

Analyst Insights

Bullish

1 day ago